-
公开(公告)号：US20240307380A1
公开(公告)日：2024-09-19
申请号：US18670637
申请日：2024-05-21
发明人： Amit ETKIN , Wei WU , Chao WANG , Nicholas COOPER , Joshua JORDAN , Adam SAVITZ
IPC分类号： A61K31/496 , A61B5/16 , A61B5/374 , A61K9/00 , A61K31/19 , A61K31/53 , A61K33/00 , A61P25/24
CPC分类号： A61K31/496 , A61K9/0053 , A61K31/19 , A61K31/53 , A61K33/00 , A61P25/24 , A61B5/165 , A61B5/374
摘要： This invention relates to the use of (4-benzylpiperazin-1-yl)-[2-(3-methylbutylamino)pyridin-3-yl]methanone (NSI-189) or a pharmaceutically acceptable salt thereof in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder (MDD), bipolar disorder, post-traumatic stress disorder, substance use disorder, and depression-related aspects of schizophrenia (e.g. negative symptoms) in select patients who exhibit impaired learning and/or memory. The invention also relates to the use of NSI-189 or a pharmaceutically acceptable salt thereof in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder (MDD), in select patients who exhibit impaired learning and/or memory or certain EEG characteristics.
-
公开(公告)号：US20240307378A1
公开(公告)日：2024-09-19
申请号：US18670619
申请日：2024-05-21
发明人： Amit ETKIN , Wei WU , Chao WANG , Nicholas COOPER , Joshua JORDAN , Adam SAVITZ
IPC分类号： A61K31/496 , A61K9/00 , A61K31/554 , A61P25/24
CPC分类号： A61K31/496 , A61K9/0053 , A61K31/554 , A61P25/24
摘要： This invention relates to the use of (4-benzylpiperazin-1-yl)-[2-(3-methylbutylamino)pyridin-3-yl]methanone (NSI-189) or a pharmaceutically acceptable salt thereof in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder (MIDD), bipolar disorder, post-traumatic stress disorder, substance use disorder, and depression-related aspects of schizophrenia (e.g. negative symptoms) in select patients who exhibit impaired learning and/or memory. The invention also relates to the use of NSI-189 or a pharmaceutically acceptable salt thereof in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder (MDD), in select patients who exhibit impaired learning and/or memory or certain EEG characteristics.
-
公开(公告)号：US20240307379A1
公开(公告)日：2024-09-19
申请号：US18670627
申请日：2024-05-21
发明人： Amit ETKIN , Wei WU , Chao WANG , Nicholas COOPER , Joshua JORDAN , Adam SAVITZ
IPC分类号： A61K31/496 , A61B5/16
CPC分类号： A61K31/496 , A61B5/165
摘要： This invention relates to the use of (4-benzylpiperazin-1-yl)-[2-(3-methylbutylamino)pyridin-3-yl]methanone (NSI-189) or a pharmaceutically acceptable salt thereof in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder (MIDD), bipolar disorder, post-traumatic stress disorder, substance use disorder, and depression-related aspects of schizophrenia (e.g. negative symptoms) in select patients who exhibit impaired learning and/or memory. The invention also relates to the use of NSI-189 or a pharmaceutically acceptable salt thereof in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder (MDD), in select patients who exhibit impaired learning and/or memory or certain EEG characteristics.
-
公开(公告)号：US20220387424A1
公开(公告)日：2022-12-08
申请号：US17805374
申请日：2022-06-03
发明人： Amit ETKIN , Dan SEGAL , Wei WU , Li Shen , Vinit Shah , Adam Savitz
IPC分类号： A61K31/496 , A61P25/24
摘要： This invention relates to the use of (4-benzylpiperazin-1-yl)-[2-(3-methylbutylamino)pyridin-3-yl]methanone (NSI-189) or a pharmaceutically acceptable salt thereof in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder, bipolar disorder, posttraumatic stress disorder, substance use disorder, and depression-related aspects of schizophrenia (e.g. negative symptoms), in a patient who is cognitively impaired or has poor or slow cognition or difficulty making decisions or exhibits certain EEG properties. The present invention also relates to the selection of patients with a biomarker (e.g., EEG) and/or clinical symptoms who would most benefit from such compounds.
-
公开(公告)号：US20240197721A1
公开(公告)日：2024-06-20
申请号：US18528486
申请日：2023-12-04
发明人： Amit ETKIN , Wei WU , Chao WANG , Nicholas COOPER , Josh JORDAN , Adam SAVITZ
CPC分类号： A61K31/496 , A61B5/165 , A61B5/372 , A61K9/0053 , A61K45/06 , A61P25/24
摘要： This invention relates to the use of (4-benzylpiperazin-1-yl)-[2-(3-methylbutylamino)pyridin-3-yl]methanone (NSI-189) or a pharmaceutically acceptable salt thereof in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder (MDD), bipolar disorder, post-traumatic stress disorder, substance use disorder, and depression-related aspects of schizophrenia (e.g. negative symptoms) in select patients who exhibit impaired learning and/or memory. The invention also relates to the use of NSI-189 or a pharmaceutically acceptable salt thereof in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder (MDD), in select patients who exhibit impaired learning and/or memory or certain EEG characteristics.
-
公开(公告)号：US20240342165A1
公开(公告)日：2024-10-17
申请号：US18670604
申请日：2024-05-21
发明人： Amit ETKIN , Dan SEGAL , Wei WU , Li SHEN , Vinit SHAH , Adam SAVITZ
IPC分类号： A61K31/496 , A61K45/06 , A61P25/24 , A61P25/28
CPC分类号： A61K31/496 , A61K45/06 , A61P25/24 , A61P25/28
摘要： This invention relates to the use of (4-benzylpiperazin-1-yl)-[2-(3-methylbutylamino)pyridin-3-yl]methanone (NSI-189) or a pharmaceutically acceptable salt thereof in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder, bipolar disorder, posttraumatic stress disorder, substance use disorder, and depression-related aspects of schizophrenia (e.g. negative symptoms), in a patient who is cognitively impaired or has poor or slow cognition or difficulty making decisions or exhibits certain EEG properties. The present invention also relates to the selection of patients with a biomarker (e.g., EEG) and/or clinical symptoms who would most benefit from such compounds.
-
公开(公告)号：US20240342164A1
公开(公告)日：2024-10-17
申请号：US18670580
申请日：2024-05-21
发明人： Amit ETKIN , Dan SEGAL , Wei WU , Li SHEN , Vinit SHAH , Adam SAVITZ
IPC分类号： A61K31/496 , A61K9/00 , A61P25/28
CPC分类号： A61K31/496 , A61K9/0053 , A61P25/28
摘要： This invention relates to the use of (4-benzylpiperazin-1-yl)-[2-(3-methylbutylamino) pyridin-3-yl]methanone (NSI-189) or a pharmaceutically acceptable salt thereof in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder, bipolar disorder, posttraumatic stress disorder, substance use disorder, and depression-related aspects of schizophrenia (e.g. negative symptoms), in a patient who is cognitively impaired or has poor or slow cognition or difficulty making decisions or exhibits certain EEG properties. The present invention also relates to the selection of patients with a biomarker (e.g., EEG) and/or clinical symptoms who would most benefit from such compounds.
-
公开(公告)号：US20240307377A1
公开(公告)日：2024-09-19
申请号：US18670599
申请日：2024-05-21
发明人： Amit ETKIN , Dan SEGAL , Wei WU , Li SHEN , Vinit SHAH , Adam SAVITZ
IPC分类号： A61K31/496 , A61K9/00 , A61K31/138 , A61K31/15 , A61K31/165 , A61K31/343 , A61K31/36 , A61K31/381 , A61P25/24
CPC分类号： A61K31/496 , A61K9/0053 , A61K31/138 , A61K31/15 , A61K31/165 , A61K31/343 , A61K31/36 , A61K31/381 , A61P25/24
摘要： This invention relates to the use of (4-benzylpiperazin-1-yl)-[2-(3-methylbutylamino)pyridin-3-yl]methanone (NSI-189) or a pharmaceutically acceptable salt thereof in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder, bipolar disorder, posttraumatic stress disorder, substance use disorder, and depression-related aspects of schizophrenia (e.g. negative symptoms), in a patient who is cognitively impaired or has poor or slow cognition or difficulty making decisions or exhibits certain EEG properties. The present invention also relates to the selection of patients with a biomarker (e.g., EEG) and/or clinical symptoms who would most benefit from such compounds.
-
公开(公告)号：US20240316016A1
公开(公告)日：2024-09-26
申请号：US18670632
申请日：2024-05-21
发明人： Amit ETKIN , Wei WU , Chao WANG , Nicholas COOPER , Joshua JORDAN , Adam SAVITZ
IPC分类号： A61K31/4402 , A61K9/00 , A61K45/06 , A61P25/28
CPC分类号： A61K31/4402 , A61K9/0053 , A61K45/06 , A61P25/28
摘要： This invention relates to the use of (4-benzylpiperazin-1-yl)-[2-(3-methylbutylamino)pyridin-3-yl]methanone (NSI-189) or a pharmaceutically acceptable salt thereof in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder (MIDD), bipolar disorder, post-traumatic stress disorder, substance use disorder, and depression-related aspects of schizophrenia (e.g. negative symptoms) in select patients who exhibit impaired learning and/or memory. The invention also relates to the use of NSI-189 or a pharmaceutically acceptable salt thereof in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder (MDD), in select patients who exhibit impaired learning and/or memory or certain EEG characteristics.
-
公开(公告)号：US20240307376A1
公开(公告)日：2024-09-19
申请号：US18670588
申请日：2024-05-21
发明人： Amit ETKIN , Dan SEGAL , Wei WU , Li SHEN , Vinit SHAH , Adam SAVITZ
IPC分类号： A61K31/496 , A61P25/24 , G16H20/10
CPC分类号： A61K31/496 , A61P25/24 , G16H20/10
摘要： This invention relates to the use of (4-benzylpiperazin-1-yl)-[2-(3-methylbutylamino)pyridin-3-yl]methanone (NSI-189) or a pharmaceutically acceptable salt thereof in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder, bipolar disorder, posttraumatic stress disorder, substance use disorder, and depression-related aspects of schizophrenia (e.g. negative symptoms), in a patient who is cognitively impaired or has poor or slow cognition or difficulty making decisions or exhibits certain EEG properties. The present invention also relates to the selection of patients with a biomarker (e.g., EEG) and/or clinical symptoms who would most benefit from such compounds.
-
-
-
-
-
-
-
-
-
搜索结果
11 条记录 (耗时 0.014 秒)
